In this interview, PAREA founder, Tadeusz Hawrot, reflects on the policy landscape, regulatory challenges, and the future of access to these emerging treatments in the EU.

The topics in this episode:

• Introduction to PAREA

• Why is Europe Lagging Behind the USA in Psychedelic Science?

• Which Psychedelic Substances Have the Greatest Potential to Become Medicines in the EU?

• Is There Potential in National Legislation, Such as in the Czech Republic?

• What Should Be Done About the Grey Areas of Psychedelic Treatment?

• How Can Professionals Be Trained in Psychedelic Treatment?

Interview: Péter Sárosi
Video: István Gábor Takács